Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Women ≥ 18 years of age~2. Histologically documented breast cancer (either primary or metastatic site) that is (i) ER-negative (0), (ii) PR-negative (0), and (iii) HER2-negative, defined by IHC (immunohistochemistry; IHC 0/1, non-overexpressing) or FISH (fluorescence in situ hybridization; FISH negative) or CISH (chromogen in situ hybridization; CISH negative).~3. Expression of LHRH receptor confirmed by IHC on archival (or current biopsy of breast tumor or metastatic site) breast cancer tissue~4. Progressive disease after failure of 1 to 3 prior chemotherapy regimens for recurrent or metastatic (Stage IV) disease (prior adjuvant/neoadjuvant therapy is allowed)~5. Measurable disease by RECIST 1.1 criteria; at least one target lesion that has not been previously irradiated.~Exclusion Criteria:~1. Eastern Cooperative Oncology Group (ECOG) performance status \> 2~2. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or recent myocardial infarction (within 6 months of enrollment)~3. Leptomeningeal disease or brain metastases requiring steroids or other therapeutic intervention~4. Left ventricular ejection fraction (LVEF) \< 50 %, determined by echocardiogram or MUGA scan~5. Compromised organ or marrow function as evidenced by any of the following:~   * thrombocyte count: \< 100x109/L~  * absolute neutrophil count (ANC): \< 1.5x109/L~  * hemoglobin: \< 6.0 mmol/L (\< 9 g/100 mL)~  * AS(A)T, AL(A)T: \> 2.5 times upper limit of normal range (ULN) (\> 5x ULN if clearly related to liver metastases)~  * bilirubin: \> 1.5 mg/dL~  * creatinine: \> 1.5 mg/dL or creatinine clearance \< 40 mL/min.~6. Systemic anticancer therapy or radiotherapy within 21 calendar days of the first dose of study drug\*)~   \* also excluded are patients with anticipated ongoing concomitant anticancer therapy during the study~7. Prior exposure to anthracyclines or anthracenediones for the treatment of metastatic breast cancer including liposomal doxorubicin (Doxil), doxorubicin, daunorubicin, or mitoxantrone~8. Prior adjuvant anthracyclines with a cumulative anthracycline dose ≥ 300 mg/m2~9. Ongoing therapeutic anticoagulation~10. Patients who are not surgically sterile or post-menopausal must agree to use for the duration of the study reliable methods of birth control defined as:~    * complete abstinence~   * any intrauterine device (IUD) with published data showing that the lowest expected failure rate is \< 1 % per year, or~   * any other methods with published data showing that the lowest expected failure rate is less than 1 % per year~11. Investigational therapy within 30 calendar days of the first scheduled day of protocol treatment (investigational therapy is defined as treatment for which there is currently no regulatory authority approved indication).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: AEZS-108 (Type: EXPERIMENTAL): Intervention: AEZS-108 (267 mg/m\^2, 2-hour IV infusion every Day 1 of a 21-day (3-week) cycle). Recommended prophylactic anti-emetic for AEZS-108: 8 mg dexamethasone
- Arm B: Standard (SCCC) (Type: ACTIVE_COMPARATOR): commercially available standard single agent cytotoxic chemotherapy (SSCC): - doses below the recommended package insert at the discretion of treating oncologist;~- on a 21-day cycle (although weekly administration is allowed; note: pegylated liposomal doxorubicin will be administered on a 28-day cycle).

Based on this trial design, predict the completion outcome and termination type (if applicable).